Information
Regulated n.
20259-18-2026Date/Time of Dissemination Start July 9, 2026 17:45:01Euronext Growth Milan
Company: LABORATORIO FARMACEUTICO ERFO
User - contact person: ERFON02 - Travisano Daniele
Type: 3.1
Date/Time of Receipt: July 9, 2026 17:45:01 Date/Time of Dissemination Start: July 9, 2026 17:45:01 Subject: Laboratorio Farmaceutico Erfo S.p.A. -
Vesting of the tranche of the "ERFO 2025-2027 stock grant plan" Press release text
See attachment
PRESS RELEASE
Laboratorio Farmaceutico Erfo S.p.A.
Viale Geki Russo 9 98049 Villafranca Tirrena (ME) VAT No. 03247570835 - Share Capital €1,750,000 fully paid-up Tel. 090 914 6125 - E-mail: info@erfo.it - Certified E-mail: erfospa@pec.it www.erfo.it - www.dietnatural.it
ERFO: VESTING OF THE FIRST TRANCHE
OF THE “ERFO 2025-2027 STOCK GRANT PLAN”
A TOTAL OF 152,955 RIGHTS TO RECEIVE CONFIRMED, CORRESPONDING TO AS MANY ORDINARY SHARES GRANTED FREE OF CHARGE
THE PLAN WILL BE SERVICED EXCLUSIVELY WITH OWN SHARES ALREADY HELD IN PORTFOLIO:
NO NEW ISSUANCE OR DILUTIVE EFFECT ON CAPITAL
Villafranca Tirrena (ME), July 09, 2026
Laboratorio Farmaceutico Erfo S.p.A. S.B. (“Erfo” or the “Company”), an Innovative SME and benefit company operating in the nutraceutical sector and listed on Euronext Growth Milan (Ticker: ERFO), announces the vesting of the Rights to Receive related to the First Tranche of the “ERFO 2025-2027 Stock Grant Plan” (the “Plan”), approved by the Board of Directors on November 10, 2025, and intended for the management and employees of the Group. It is reminded that the Plan is intended for directors, employees, and collaborators of the Company and/or its subsidiaries in order to pursue objectives of aligning the interests of management with those of shareholders, retaining key personnel, and developing the network of the subsidiary Fit&Go, which have been duly identified by the Company's Board of Directors based on the roles they hold.
Today, following verification of the existence of the conditions set forth in the relevant regulations1 with reference to the results of the 2025 financial year, the Board of Directors has approved the vesting of a total of 152,955 Rights to Receive, granting – free of charge – as many ordinary shares of the Company, in favor of 10 beneficiaries of the Plan.
Plan Servicing Method
The Plan will be serviced exclusively through the Company's own shares already held in portfolio. Therefore, there will be no capital increase or issuance of new shares: the allocation of shares to beneficiaries will not result in any dilutive effect for shareholders, and the share capital and the total number of ordinary shares of the Company will remain unchanged.
Timelines and Exercise of Rights
The Allocation Certificates will be sent to the entitled beneficiaries by July 14, 2026. The Vested Rights to Receive may be exercised during the Exercise Period, between June 30 and July 30, 2026. The shares allocated to the Chairman and CEO are subject to a lock-up period of 365 days from the date of actual allocation.
1 For further information, please refer to the press release regarding the approval of the Plan's implementation regulations: PRESS RELEASE approval of implementation regulations
PRESS RELEASE
Laboratorio Farmaceutico Erfo S.p.A.
Viale Geki Russo 9 98049 Villafranca Tirrena (ME) VAT No. 03247570835 - Share Capital €1,750,000 fully paid-up Tel. 090 914 6125 - E-mail: info@erfo.it - Certified E-mail: erfospa@pec.it www.erfo.it - www.dietnatural.it *** This press release is available on the Borsa Italiana website, the company's website www.erfo.it, Investor Relations Section, and on www.emarketstorage.it
IDENTIFICATION CODES
Ordinary Shares | ISIN IT0005497885 | Ticker: ERFO
THE COMPANY
Laboratorio Farmaceutico Erfo S.p.A. is an Innovative SME integrated across the entire supply chain, specializing in the formulation, production, and marketing of nutraceutical products. The company is currently at the center of an ecosystem of brands developed primarily through franchising, with over 270 points of sale in Europe, focused on 360-degree nutrition and well-being.
The company operates through 4 business lines: 1. Diètnatural: a format conceived and developed by the company dedicated to the sale of nutraceutical products and continuous support in nutritional therapy. 2. Medical Division: a line of nutraceuticals launched in 2021, dedicated to specific therapeutic areas (gastroenterological, neurological, and musculoskeletal) with significant developments planned in the orthopedic area. 3. BodySano: a format developed in France and Belgium, which integrates the sale of nutraceutical products, continuous support in nutritional paths, and innovative aesthetic treatments. 4. Fit And Go: a leading franchising network in Italy in the high-tech fitness and fast fitness sector, offering tailor-made training programs focused on well-being and health.
The Company's strategy is to invest in the development of its various business lines, particularly through: i) new openings of different franchising formats across Europe; ii) production and marketing of new products and services related to the 360-degree wellness world; iii) development of the Medical Division line both in terms of products (i.e., R&D) and commercial network; iv) investments in marketing and digitalization to support the entire ecosystem.
FOR FURTHER INFORMATION:
ISSUER
Erfo
Viale Geki Russo Lo. Pontegallo, 98049 Villafranca T. (Me) Tel. +39 090 914 6125 Daniele Travisano : ir@erfo.it EURONEXT GROWTH ADVISOR
illimity Bank
Via Soperga, 9 - 20124 Milan Tel. +39 02 82849699
Mail: erfo@furstenberg.eu
INVESTOR & MEDIA RELATIONS ADVISOR
IR Top Consulting Via Bigli, 19 - 20121 Milan Tel. +39 02 45473883
Domenico Gentile,
Mail: ufficiostampa@irtop.com
End of Release n.20259-18-2026 Number of Pages: 4